Skip to main content

The Global Kidney Cancer Drugs Market Is Witnessing High Growth Owing To the Increasing Prevalence of Kidney Cancer Cases in the World

 


Market Overview:

Kidney cancer is a serious medical condition. There are several types of the disease, including medullary and sarcoma, which are less common but highly aggressive. They develop in the soft tissue surrounding the kidney, as well as in the fat that surrounds it. Surgical removal of the affected organ is the standard treatment for this type of cancer. However, if the disease has spread to other organs or spreads beyond the kidney, chemotherapy or systemic therapy may be needed. A biopsy is another test for kidney cancer. It involves inserting a thin needle into a tumor and looking through the tissue under a microscope to detect cancer cells. Biopsies aren't always accurate, and the healthcare provider may not recommend them. If the tumor has spread to lymph nodes or is large, a biopsy may be performed. This will allow the doctor to evaluate the tumor's location and the extent of its spread and determine its stage and aggressiveness.

Competitive Landscape:

Major players operating in the global kidney cancer drugs market include Quest Diagnostics Incorporated, Illumina Inc, Rosetta Genomics, Sysmex Corporation, NanoString Technologies Inc, NeoGenomics Laboratories, Myriad Genetics Inc, Argos Therapeutics, Prometheus Laboratories, Immatics Biotechnologies, Aveo Pharmaceuticals, Abbott Laboratories, Onyx, Cipla Limited, Roche, Eisai, Bristol-Myers Squibb, Thermo Fisher Scientific Inc, Amgen, Active Biotech, GlaxoSmithKline Plc, Genentech Inc., F. Hoffmann-La Roche Ag, Exelixis Inc, Novartis International AG, Pfizer Inc., and Bayer AG.

Key Market Drivers:

The increasing incidence of kidney cancer cases in the world is expected to augment the growth of the global kidney cancer drugs market. For instance, according to Cancer.Net, in 2020, around 431,288 individuals in the world were suffering from kidney cancer. Targeted drug therapy uses drugs or substances to attack the cancer cells in a specific area of the body. This can reduce side effects caused by the drugs while still killing the cancer cells. Anti-angiogenic agents block the growth of the blood vessels feeding the tumor. A multikinase inhibitor can stop the growth of cancer cells, while a tyrosine kinase inhibitor works by blocking an enzyme that helps the cancer cells grow. Increasing treatment launches by key players are estimated to enhance the growth of the global kidney cancer drugs market. 

Covid-19 Impact Analysis

During the COVID-19 pandemic, the increasing focus on the virus-infected cases affected the growth of the global kidney cancer drugs market.  Moreover, sudden stress on the healthcare sector also impacted the market growth.

Key Takeaways

·         North America is expected to dominate the growth of the global kidney cancer drugs market, owing to the increasing prevalence of kidney cancer cases in the region. For instance, according to Cancer.Net, in 2020 around 79,000 adults in the U.S. were diagnosed with kidney cancer.

·         The Asia Pacific is estimated to witness high growth in the global kidney cancer drugs market, owing to the increasing expansion of cancer hospitals in the region. For instance, according to the Indian Cancer Society, India has around 27 dedicated cancer hospitals currently.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Fc Protein and Glycoengineered Antibodies Market Is Booming Worldwide 2023-2028

  Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.  Increasing preva...
Post a Comment
Read more

Breathalyzers Market Development Analysis Contributing Top Vendor Landscape and Economic Growth 2028

  The breathalyzer market refers to the sales and distribution of devices used for measuring blood alcohol content (BAC) through analysis of a breath sample. These devices are widely used by law enforcement agencies for detecting drunk drivers and in workplaces for alcohol screening. The market has been growing due to increasing awareness about the dangers of drunk driving, stricter laws and penalties, and advancements in technology that have made breathalyzers more portable and user-friendly. The market is expected to continue growing in the future as demand for personal and professional use breathalyzers increases. Breathalyzers are instruments used for testing blood alcohol levels through an individual’s breath. These devices find application in probation departments, police departments, remand homes, and commercial sector. The global breathalyzers market is estimated to account for  US$ 6,384.5 Mn  in terms of value in 2020 and is expected to reach  US$ 71,8...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more